Search

R-1487

XC221

XC221 was investigated in clinical trials to treat patients with respiratory infections, including influenza, COVID-19, and other acute viral upper respiratory infections.

Osanetant

In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. … Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System

Taranabant

Anacetrapib

Valrocemide

GMK

GMK vaccine (a ganglioside conjugate vaccine coupled to keyhole limpet hemocyanin and formulated with the adjuvant QS-21) for the potential treatment of melanoma

Influenza B virus B/Austria/1359417/2021 live (attenuated) antigen

Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

Influenza A virus A/Darwin/6/2021 IVR-227 (H3N2) antigen (formaldehyde inactivated)

Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

Influenza B virus B/Singapore/WUH4618/2021 antigen (MDCK cell derived, propiolactone inactivated)

Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen